Biopharmx Corp (NYSEAMERICAN:BPMX) CEO David S. Tierney bought 100,000 shares of Biopharmx stock in a transaction dated Wednesday, September 19th. The shares were bought at an average price of $0.20 per share, for a total transaction of $20,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NYSEAMERICAN BPMX opened at $0.19 on Friday. Biopharmx Corp has a fifty-two week low of $0.10 and a fifty-two week high of $0.38.
Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings data on Thursday, August 30th. The biotechnology company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Further Reading: Understanding Stock Ratings
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.